Can a prostate implant ease urinary problems during cancer radiation?

NCT ID NCT05311527

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This completed Phase I safety trial tested whether using the UroLift system—a device that lifts and holds enlarged prostate tissue out of the way—before stereotactic ablative body radiotherapy (SABR) is safe for men with both prostate cancer and benign prostatic hyperplasia (BPH). Fifteen men with low- to intermediate-risk prostate cancer and BPH received the UroLift implant followed by SABR. The main goal was to check for serious complications within 90 days after treatment, with secondary goals looking at urinary, sexual, and bowel quality of life.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
UroLift implant and stereotactic ablative body radiotherapy (SABR)
What this could lead to
If successful, this approach could offer a way to manage BPH symptoms during prostate cancer radiation, potentially improving urinary quality of life.
What could go wrong
This is a very small, early safety trial with only 15 participants, so results may not apply widely. The combination could still cause unexpected side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BENIGN PROSTATIC HYPERPLASIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • University of Texas Southwestern Medical Center - Dallas

    Dallas, Texas, 75390, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.